目的：观察新黑苏嘎乌日勒治疗缺血性卒中后抑郁症的疗效与安全性。方法：选取内蒙古国际蒙医医院门诊及住院患者共100例，将符合纳入标准的患者随机分为实验组及对照组，各50例；两组患者均给予缺血性卒中的基础治疗，实验组给予蒙药新黑苏嘎乌日勒，对照组给予西药黛力新；比较治疗前后的汉密尔顿抑郁量表（HAMD-17）评分、抑郁自评量表（SDS）评分和日常生活活动能力ADL（Barthel指数）评分的差异。结果：总有效率分别为实验组88%和对照组76%，差异有统计学意义(P<0.05)。治疗后HAMD-17和SDS量表评分下降，实验组低于对照组，差异有统计学意义(P<0.05)。两组治疗后ADL量表评分均有改善，较对照组有统计学意义(P<0.05)。两组在治疗前后均进行常规安全性检查，无异常。结论：蒙药新黑苏嘎乌日勒治疗缺血性卒中后抑郁症临床疗效显著，对患者抑郁状态的改善程度明显优于对照组，值得在临床实践中得到推广和应用。

Objective: To observe the efficacy and safety of the Mongolian medicine new Hesugawurile in the treatment of depression after ischemic stroke. Methods: A total of 100 outpatients and inpatients in the Inner Mongolia International Mongolian Hospital were selected from March 2020 to May 2021. Patients who met the inclusion criteria were randomized into experimental and control groups with 50 cases each; both groups were given the basic treatment of ischemic stroke. On this basis, the experimental group was given the Mongolian medicine new Hesugawurile, and the control group was given the western medicine Deanxit (Flupentixol and meritroxine tablets); Ratings of the Hamilton Depression Scale (HAMD-17), the Self-rated Depression Scale (SDS), and the Activity of Daily Life (ADL) were compared before and after treatment. Results: The total efficiency was 88% and 76% in controls, and statistically significant (P<0.05).After treatment, the HAMD-17 and SDS scale scores decreased in both groups, with the experimental group scoring lower than the control group, with statistically significant differences (P<0.05). The ADL scale scores of the two groups were improved after treatment, and the score of the experimental group was higher than that of the control group, the difference was statistically significant (P<0.05). Before and after treatment, the blood and urine routine, liver function, renal function, electrocardiogram and other safety tests were performed in the two groups. There was no abnormality, and no discomfort symptoms and no adverse reactions occurred during the medication. Conclusion: The Mongolian medicine new Hesugawurile has significant clinical efficacy in the treatment of depression after ischemic stroke. The improvement of depression and the recovery of activities of daily living are significantly better than those in the control group, which is worthy of clinical application.

蒙药新黑苏嘎乌日勒治疗缺血性卒中后抑郁症的临床疗效研究